NASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis $5.90 -0.02 (-0.34%) Closing price 03:58 PM EasternExtended Trading$5.94 +0.04 (+0.76%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenax Therapeutics Stock (NASDAQ:TENX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenax Therapeutics alerts:Sign Up Key Stats Today's Range$5.90▼$6.0150-Day Range$5.62▼$6.2452-Week Range$3.25▼$7.89Volume18,913 shsAverage Volume28,811 shsMarket Capitalization$26.90 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingBuy Company Overview Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Read More Tenax Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreTENX MarketRank™: Tenax Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 802nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenax Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenax Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenax Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenax Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenax Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.22% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Tenax Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.22% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Tenax Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving. News and Social Media1.2 / 5News Sentiment-0.85 News SentimentTenax Therapeutics has a news sentiment score of -0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tenax Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.67% of the stock of Tenax Therapeutics is held by institutions.Read more about Tenax Therapeutics' insider trading history. Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TENX Stock News HeadlinesLeerink Partnrs Has Negative Forecast for TENX Q3 EarningsAugust 19, 2025 | americanbankingnews.comWilliam Blair Brokers Decrease Earnings Estimates for TENXAugust 19, 2025 | americanbankingnews.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)Q3 EPS Estimate for Tenax Therapeutics Reduced by AnalystAugust 18, 2025 | americanbankingnews.comEquities Analysts Set Expectations for TENX FY2028 EarningsAugust 17, 2025 | americanbankingnews.comTenax Therapeutics reports Q2 EPS (27c), consensus (45c)August 14, 2025 | msn.comTenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comTENX Tenax Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comSee More Headlines TENX Stock Analysis - Frequently Asked Questions How have TENX shares performed this year? Tenax Therapeutics' stock was trading at $6.19 at the beginning of 2025. Since then, TENX shares have decreased by 2.7% and is now trading at $6.02. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its earnings results on Wednesday, August, 13th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.23. When did Tenax Therapeutics' stock split? Tenax Therapeutics shares reverse split on Wednesday, January 3rd 2024.The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/13/2025Today8/26/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TENX CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees9Year Founded1967Price Target and Rating Average Price Target for Tenax Therapeutics$17.00 High Price Target$20.00 Low Price Target$14.00 Potential Upside/Downside+182.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.34% Return on Assets-30.39% Debt Debt-to-Equity RatioN/A Current Ratio41.89 Quick Ratio41.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$26.99 per share Price / Book0.22Miscellaneous Outstanding Shares4,560,000Free Float4,393,000Market Cap$27.45 million OptionableNot Optionable Beta1.46 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:TENX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.